Nivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid Syndrome
Nivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid Syndrome
Not yet recruiting · NCT05597800 · Registry updated 2022-10-28Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Nivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid Syndrome | COVID-19, Chronic Disease, Coronaviridae Infections, Disease Attributes, Infections, Neoplasms by Site, Nidovirales infectious disease, Orthocoronavirinae infectious disease, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Post-Infectious Disorders, RNA Virus Infections, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, long COVID-19, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, pneumonia, respiratory system disorder, respiratory tract infectious disorder, respiratory tract neoplasm, viral infectious disease, viral pneumonia | Not yet recruiting | Phase 2 | 2022-10-28 | NCT05597800 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Universita di Verona | 36 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Centro Ricerche Cliniche | Verona | Italy | 1 |